您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Ondansetron-13C-d3
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Ondansetron-13C-d3
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Ondansetron-13C-d3图片
规格:98%
分子量:297.4
包装与价格:
包装价格(元)
500ug电议
1mg电议

产品介绍
A neuropeptide with diverse biological activities
货号:ajcx23188
CAS:N/A
分子式:C17[13C]H16D3N3O
分子量:297.4
溶解度:DMSO: 0.1 mg/ml
纯度:98%
存储:Store at -20°C
库存:现货

Background:

Ondansetron-13C-d3is intended for use as an internal standard for the quantification of ondansetron by GC- or LC-MS. Ondansetron is an antagonist of the serotonin (5-HT) receptor subtype 5-HT3receptor (Ki= 1.6 nM).1It is selective for the 5-HT3receptor over the 5-HT1A-D, 5-HT2, and 5-HT4receptors (Kis = >1,200 nM). It inhibits 5-HT-induced depolarization of isolated rat vagus nerve and contraction of isolated guinea pig ilium longitudinal muscle-myenteric plexus preparations in a concentration-dependent mannerex vivo.2In a ferret model of cisplatin-induced emesis, ondansetron reduces the number of retching and vomiting episodes and increases the latency time to vomit when administered at a dose of 0.01 mg/kg and eliminates retching and vomiting when administered at a dose of 0.1 mg/kg.3Ondansetron (0.5 and 1 mg/kg) also decreases immobility time in a forced swim test and increases time spent in the light chamber and latency to leave the light chamber in the light/dark exploration test in a mouse model of diabetes induced by streptozotocin , indicating antidepressant-like and anxiolytic activities.4Formulations containing ondansetron have been used in the treatment of nausea and vomiting associated with chemotherapy, radiotherapy, or following surgery.


1.van Wijingaarden, I., Hamminga, D., van Hes, R., et al.Development of high-affinity 5-HT3 receptor antagonists. Structure-affinity relationships of novel 1,7-annelated indole derivativesJournal of Medicinal Chemistry36(23)3693-3699(1993) 2.Butler, A., Hill, J.M., Ireland, S.J., et al.Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptorsBr. J. Pharmacol.94(2)397-412(1988) 3.Stables, R., Andrews, P.L.R., Bailey, H.E., et al.Antiemetic properties of the 5HT3-receptor antagonist, GR38032FCancer Treat. Rev.14(3-4)333-336(1987) 4.Gupta, D., Radhakrishnan, M., and Kurhe, Y.Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: Possible implication of serotonergic systemEur. J. Pharmacol.74459-66(2014)